Highlights

• Laurus Labs shares touched a fresh 52-week high of ₹1,433.70.
• The stock has surged 128.59% over the past one year.
• Laurus Labs operates across APIs, formulations, and CDMO services.

Laurus Labs Limited (NSE:LAURUSLABS) is a research-driven pharmaceutical and biotechnology company with operations spanning active pharmaceutical ingredients (APIs), formulations, and contract development and manufacturing services (CDMO). The company has established a presence in therapeutic categories including anti-retroviral medicines, oncology products, cardiovascular treatments, and gastro therapeutics.

Laurus Labs also provides integrated contract manufacturing solutions for global pharmaceutical innovators, supporting activities from clinical-stage drug development through to commercial-scale manufacturing.

Source: Company Filing

Diversified Pharmaceutical Operations

The company's business model combines API manufacturing, finished dosage formulations, and CDMO services. This diversified structure enables participation across multiple segments of the pharmaceutical value chain.

Laurus Labs serves domestic and international markets through manufacturing facilities approved by several global regulatory agencies, including the US Food and Drug Administration (USFDA), World Health Organization (WHO), Japan PMDA, UK MHRA, European Medicines Agency (EMA), and Australia's Therapeutic Goods Administration (TGA).

The company employs more than 6,500 people, including over 1,050 scientists, across a network of more than 11 manufacturing and research facilities.

Recent Stock Performance Reflects Strong Momentum

Laurus Labs has delivered substantial gains across key timeframes. The stock has risen 3.13% during the past week and 22.16% over the last month, significantly outperforming the Nifty Midcap 50 index during both periods.

On a year-to-date basis, the stock has advanced 28.32%, compared with a marginal decline of 0.19% in the benchmark index. The one-year performance has been particularly notable, with Laurus Labs gaining 128.59% against a 6.88% rise in the Nifty Midcap 50.

Longer-term returns have also remained significant, with gains of 311.76% over three years and 160.64% over five years.

Fresh 52-Week High Signals Continued Interest

The stock touched a new 52-week high of ₹1,433.70 on June 4, 2026. This compares with a 52-week low of ₹609.20 recorded on June 3, 2025.

The move to a new annual high highlights the sharp appreciation witnessed over the past year. The stock's annualised volatility of 38.78% indicates moderate-to-high price fluctuations, reflecting changing investor sentiment and developments within the pharmaceutical sector.

With a market capitalisation of more than ₹76,000 crore, Laurus Labs has emerged as one of the notable pharmaceutical companies in India's listed healthcare universe.

Factors Influencing The Pharmaceutical Sector

Investors tracking pharmaceutical companies often monitor product demand, regulatory approvals, manufacturing capacity utilization, export performance, research and development activities, and contract manufacturing opportunities.

For companies involved in APIs and CDMO operations, customer relationships, regulatory compliance, product pipelines, and global pharmaceutical outsourcing trends are additional factors that can influence business performance and investor sentiment.

Key Risks

• Regulatory observations at manufacturing facilities.
• Dependence on global pharmaceutical demand trends.
• Pricing pressure in API and generic drug markets.
• Customer concentration within contract manufacturing operations.

Today's Share Performance

Laurus Labs shares were trading at ₹1,423.90 on June 4, 2026, up 2.12% from the previous close of ₹1,394.30. The stock opened at ₹1,392.00 and touched an intraday high of ₹1,433.70, which also marked a fresh 52-week high. The day's low stood at ₹1,384.00. Around 8.12 lakh shares changed hands during the session, generating traded value of approximately ₹115.19 crore. The company had a market capitalisation of ₹76,924.16 crore, while its free-float market capitalisation stood at ₹55,292.39 crore.

Source: TradingView

Summary

Laurus Labs Limited (NSE:LAURUSLABS) is a research-driven pharmaceutical and biotechnology company engaged in APIs, formulations, and CDMO services. The company serves global pharmaceutical markets through a network of internationally approved manufacturing facilities. The stock has delivered gains of 128.59% over the past year and reached a fresh 52-week high of ₹1,433.70 on June 4, 2026. During the session, shares traded 2.12% higher at ₹1,423.90, extending their strong upward momentum.

FAQs

Q: What does Laurus Labs Limited do?
A: Laurus Labs manufactures APIs, formulations, and provides contract development and manufacturing services to pharmaceutical companies.

Q: What was Laurus Labs' 52-week high on June 4, 2026?
A: The stock touched a fresh 52-week high of ₹1,433.70 during trading on June 4, 2026.

Q: How has Laurus Labs performed over the last year?
A: The stock has gained 128.59% over the past one year, outperforming its benchmark index.